Eximo Medical Overview
Eximo Medical is developing hybrid catheter technology for tissue resection in vascular and gastrointestinal endoluminal applications. The companys proprietary single-use hybrid catheter, Auryon, combines optical fibers that deliver short laser pulses and a blunt mechanical knife. The Auryon system is designed to allow treatment of infrainguinal lesions both above and below the knee (including below the ankle), with a built-in off-centering mechanism for eccentric lesions in the largest catheter. The device includes built-in aspiration to address the risk of embolization. Auryon has been tested in a multinational trial in both office-based labs and hospitals.
Cumulative Funding Raised Over Time ($)
$1.6MJul 2015
$2.5MOct 2012
Latest News
growth-positive
AngioDynamics to buy Israeli co Eximo Medical
AngioDynamics Inc. has announced its agreement to acquire Eximo Medical Ltd., an Israeli laser technology developer, for $46 million and up to $20 million in milestone payments. Eximo Medical has developed a proprietary 355nm wavelength laser technology platform. The acquisition will bring a foundational technology to AngioDynamics portfolio, changing the way caregivers deliver treatment for peripheral artery disease (PAD). Eximos B-Laser technology offers a differentiated alternative to legacy atherectomy devices, providing safety, precision, and efficiency. The acquisition will enable AngioDynamics to enter a growing market with a breakthrough medical solution. Eximo will continue to operate in Israel. The event occurred on October 3, 2019.
Acquisition
growth-positive
Eximo Medical launches B-Laser Atherectomy System - Medical Design and Outsourcing
Eximo Medical has launched its B-Laser Atherectomy System for patients with arterial occlusive peripheral arterial disease. The system has shown success in treating complex and calcified lesions, and the company is experiencing commercial progress in the U.S. market. The incorporation of machine learning and photo-acoustic signal monitoring has been beneficial in characterizing materials and preventing complications. Clinicians have expressed excitement about the technology and its potential to address unmet needs in practice.
CustomersPartners
Eximo Medical Ltd. Announces First Commercial Case of Its B-Laser™ Atherectomy System in the U.S. and Publication of Its IDE and CE Studies Results
growth-positive
B-Laser, The First 355nm Laser for Peripheral Artery Disease Cleared by FDA
Eximo Medical, an Israeli-based company, has received FDA clearance for its B-Laser Atherectomy System. The system is used to clear plaque from narrowed peripheral arteries, including in-stent restenosis. The laser operates at a 355nm wavelength, which the company believes has benefits over commonly used excimer lasers. Clinical trials have shown high success rates and no major adverse events. This FDA clearance is expected to have a positive impact on the growth of Eximo Medical.
Customers
growth-positive
Eximo Medical's hybrid catheter clears pivotal trial
Eximo Medical has successfully completed a 20-patient pivotal trial in Europe for its hybrid peripheral catheter, meeting safety and efficacy endpoints. The company is pursuing CE Mark approval and plans to seek FDA approval in 2017. The trial demonstrated the devices ability to clear partial or full peripheral blockages. Eximo Medical aims to prevent complicated surgeries and amputations, providing significant pain relief and improving patients quality of life. The successful trial represents a significant milestone for the company and paves the way for a potential multi-participant FDA trial in the United States. Eximo Medical was founded by Accelmed and received a $1.6 million Series A investment round last year.
InvestmentPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $2.52M |
| Last funding | $1.6M |
| Stage | Acquired |
| Rounds | 2 |
| Investors | 4 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | www.auryon-system.com |
Locations
Prof. Haim Pekeris Street 3, Rehovot, Israel
250 Pehle Avenue, Saddle Brook, New Jersey 07663, USA
Photos & Videos
2 item(s)
Eximo Medical Business
Business models
B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersMedical Devices IndustryMedical EquipmentCore Technology
Semiconductors & ElectronicsTags (11)
cathetersgastroenterologyvascularlaserssurgerymedical-deviceshealthcare-providersclinicsdoctorscardiologyhospitalsEximo Medical Financials
$2.52M
Total funding
Undisclosed
Capital raised
$1.6M
Last funding
Acquired
Funding stage
2
Total rounds
4
Investors
Cumulative Funding Raised Over Time ($)
$1.6MJul 2015
$2.5MOct 2012
Private Equity Funding
A Round
Jul 2015
$1.6M
Accelmed, AMIT-Technion ( The Alfred Mann Institute)
Seed
Oct 2012
$921K
Accel, Peregrine Ventures
Public Offering / Exit
MNAEvent
Oct 2019
$46M
Eximo Medical Lifecycle
Cumulative Funding Raised Over Time
$1.6MJul 2015
$2.5MOct 2012
All Events
A Round
Jul 2015
$1.6M
Accelmed, AMIT-Technion ( The Alfred Mann Institute)
Seed
Oct 2012
$921K
Accel, Peregrine Ventures
MNAEvent
Oct 2019
$46M
Eximo Medical News
6 articles
growth-positive
AngioDynamics to buy Israeli co Eximo Medical
AngioDynamics Inc. has announced its agreement to acquire Eximo Medical Ltd., an Israeli laser technology developer, for $46 million and up to $20 million in milestone payments. Eximo Medical has developed a proprietary 355nm wavelength laser technology platform. The acquisition will bring a foundational technology to AngioDynamics portfolio, changing the way caregivers deliver treatment for peripheral artery disease (PAD). Eximos B-Laser technology offers a differentiated alternative to legacy atherectomy devices, providing safety, precision, and efficiency. The acquisition will enable AngioDynamics to enter a growing market with a breakthrough medical solution. Eximo will continue to operate in Israel. The event occurred on October 3, 2019.
Acquisition
growth-positive
Eximo Medical launches B-Laser Atherectomy System - Medical Design and Outsourcing
Eximo Medical has launched its B-Laser Atherectomy System for patients with arterial occlusive peripheral arterial disease. The system has shown success in treating complex and calcified lesions, and the company is experiencing commercial progress in the U.S. market. The incorporation of machine learning and photo-acoustic signal monitoring has been beneficial in characterizing materials and preventing complications. Clinicians have expressed excitement about the technology and its potential to address unmet needs in practice.
CustomersPartners
Eximo Medical Ltd. Announces First Commercial Case of Its B-Laser™ Atherectomy System in the U.S. and Publication of Its IDE and CE Studies Results
growth-positive
B-Laser, The First 355nm Laser for Peripheral Artery Disease Cleared by FDA
Eximo Medical, an Israeli-based company, has received FDA clearance for its B-Laser Atherectomy System. The system is used to clear plaque from narrowed peripheral arteries, including in-stent restenosis. The laser operates at a 355nm wavelength, which the company believes has benefits over commonly used excimer lasers. Clinical trials have shown high success rates and no major adverse events. This FDA clearance is expected to have a positive impact on the growth of Eximo Medical.
Customers
growth-positive
Eximo Medical's hybrid catheter clears pivotal trial
Eximo Medical has successfully completed a 20-patient pivotal trial in Europe for its hybrid peripheral catheter, meeting safety and efficacy endpoints. The company is pursuing CE Mark approval and plans to seek FDA approval in 2017. The trial demonstrated the devices ability to clear partial or full peripheral blockages. Eximo Medical aims to prevent complicated surgeries and amputations, providing significant pain relief and improving patients quality of life. The successful trial represents a significant milestone for the company and paves the way for a potential multi-participant FDA trial in the United States. Eximo Medical was founded by Accelmed and received a $1.6 million Series A investment round last year.
InvestmentPartners
growth-positive
Catheter developer Eximo Medical raises $1.6m
Eximo Medical has completed its Series A financing round of $1.6 million. The funding will be used for human clinical trials of its hybrid catheters. The companys patented Cathi technology combines laser ablation capabilities with a mechanical blunt blade, potentially improving accuracy and precision in treating vessel blockages. The catheters will be tested in human studies in Europe and Israel in the fourth quarter of this year. Eximos product pipeline includes solutions for Lead Extraction and interventional gastrointestinal procedures. The company aims to address the multi-billion market of Peripheral Artery Disease (PAD), which affects millions of Americans and is the underlying cause of limb amputations.
InvestmentExpand
Eximo Medical Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 11 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 9 classification IDs that could be used for matching.
Eximo Medical Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 91/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 514804079 |
| Crunchbase | eximo-medical |
| Phone | +97286307630 |
| Creator | Paz Eliav |
| Creator email | paze@cet.ac.il |
| Last updater | Orli Wollner |
| Updater email | orlushka@gmail.com |
| Last update | 2020-12-15T00:00:00.000Z |
| Created | 2014-11-30T00:00:00.000Z |
| Status detail | Acquired by AngioDynamics on Oct, 2019 |